share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

SEC announcement ·  May 28 18:07
Summary by Futu AI
Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program. Initiated on May 6, 2024, the program is part of a larger 12-month buyback plan, which began on February 6, 2024, with a total budget of up to DKK 20 billion. As of May 27, 2024, Novo Nordisk has repurchased 436,152 B shares under the current program, amounting to DKK 397,178,886. The transactions were made between May 17 and May 24, 2024, with the purchase prices ranging from DKK 906.86 to DKK 937.21 per B share. Overall, since the start of the buyback plan in February, the company has acquired 9,170,402 B shares at an average price of DKK 864.18, totaling DKK 7,924,913,659. These repurchased shares are part of the company's treasury shares, which now total 10,535,966 B shares, representing 0.2% of the share capital. Novo Nordisk, established in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and has a presence in 80 countries, with its products marketed in approximately 170 countries.
Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program. Initiated on May 6, 2024, the program is part of a larger 12-month buyback plan, which began on February 6, 2024, with a total budget of up to DKK 20 billion. As of May 27, 2024, Novo Nordisk has repurchased 436,152 B shares under the current program, amounting to DKK 397,178,886. The transactions were made between May 17 and May 24, 2024, with the purchase prices ranging from DKK 906.86 to DKK 937.21 per B share. Overall, since the start of the buyback plan in February, the company has acquired 9,170,402 B shares at an average price of DKK 864.18, totaling DKK 7,924,913,659. These repurchased shares are part of the company's treasury shares, which now total 10,535,966 B shares, representing 0.2% of the share capital. Novo Nordisk, established in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and has a presence in 80 countries, with its products marketed in approximately 170 countries.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.